Posts

FDA Extends Capricor’s Deramiocel Decision Date to November 22

on

Capricor surges on plan to amend DMD filing after adcom setback

on

Rare Disease Drugmakers Watch FDA for Renewed Focus on Therapies

on

FDA Committee Rejects Capricor's Duchenne Cell Therapy Amid Statistical Dispute

on

FDA disputes Capricor's claims of Phase 3 success for DMD cell therapy, deramiocel

on

Capricor Shares Plunge After FDA Says DMD Therapy Lacks Efficacy Ahead of Advisory Committee Meeting

on

Capricor Claims FDA Misinterpreted Efficacy Data Leading to Rejection of DMD Therapy

on

FDA Rejects Capricor's Cell Therapy for Duchenne Muscular Dystrophy

on

Capricor shares turn red as FDA plans deramiocel adcomm, likely the first under new commissioner

on